Internalization-defective mutants of somatostatin receptor subtype 2 exert normal signaling functions in hematopoietic cells  by Oomen, Sigrid P.M.A. et al.
Internalization-defective mutants of somatostatin receptor subtype 2
exert normal signaling functions in hematopoietic cells
Sigrid P.M.A. Oomena, Leo J. Ho£andb, Steven W.J. Lambertsb, Bob Lo«wenberga,
Ivo P. Touwa;*
aInstitute of Hematology, Erasmus University Rotterdam (Room H Ee 1314), P.O. Box 1738, 3000 DR Rotterdam, The Netherlands
bDepartment of Internal Medicine, Erasmus University Rotterdam, 3000 DR Rotterdam, The Netherlands
Received 16 July 2001; accepted 19 July 2001
First published online 1 August 2001
Edited by Felix Wieland
Abstract The regulatory peptide somatostatin (SST) acts via a
family of G-protein-coupled receptors comprising five subtypes
(SSTR1^5). G-protein-coupled receptors activate multiple sig-
naling mechanisms, which variably depend on internalization and
intracellular routing of activated receptors. We have recently
demonstrated that hematopoietic precursors express SSTR2 and
that SST is a chemoattractant for these cells. Herein, we
characterize critical regions in SSTR2 involved in endocytosis
and describe how ligand-induced internalization impacts on two
major signaling functions of SSTR2 in hematopoietic cells, the
activation of the Erk pathway and the induction of promigratory
responses. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The somatostatin (SST) peptides SST-14 and SST-28 regu-
late a variety of cellular functions through binding to a family
of G-protein-coupled receptors (GPCRs) [1]. Five subtypes of
human somatostatin receptors (SSTRs) have been identi¢ed,
which are encoded by related genes localized on di¡erent
chromosomes [2]. Although individual SSTR subtypes share
a high degree of structural conservation and display some
overlapping functions, they also exhibit distinct functional
properties, for example with regard to ligand binding and
kinetics of receptor internalization [3^5]. A common property
of GPCRs is their ability to regulate responsiveness to con-
tinued agonist exposure [6]. Typically, this involves desensiti-
zation of the receptor due to uncoupling from G-proteins, as
well as receptor internalization and degradation [6]. Internal-
ization and intracellular tra⁄cking of GPCRs may have a
major impact on the signaling properties of these receptors.
For instance, it was demonstrated that Erk1/Erk2 activation
by lysophosphatidic acid, thrombin and L2 adrenergic recep-
tors is endocytosis-dependent [7].
The structural determinants involved in the internalization
of receptor subtypes SSTR1^5 have been partly characterized.
Mutational analysis has demonstrated that phosphorylation
of cytoplasmic threonine and serine residues in the carboxyl
terminus of SSTR2 plays a major role in agonist-induced
desensitization and internalization [3,8,9]. Notably, internal-
ization of SSTR subtypes may vary considerably depending
on the cell type studied [3,4].
We have recently shown that SSTR2 is expressed in both
human and mouse hematopoietic systems and that SST acts
as a potent chemoattractant for hematopoietic cells. Interest-
ingly, SSTR2 expression is restricted to primitive (CD34)
precursor cells [10]. SSTRs are also expressed in various hem-
atological malignancies, including lymphomas [11,12], acute
myeloid leukemias (AML) and lymphoblastic leukemias [13^
15]. Similar to normal hematopoietic progenitors, human
AML cells express SSTR2, but none of the other SSTR sub-
types [15]. Whether ligand-induced internalization of SSTR2
takes place in hematopoietic cells and how this in£uences
SST-induced responses of these cell types has not been estab-
lished. In the present study, we show that the majority of
SSTR2s are rapidly internalized upon ligand binding and
identify a dileucine-containing motif in the C-terminus of
SSTR2 as being an important regulatory domain for endocy-
tosis. Quite surprisingly, we observed that two major signaling
functions of SSTR2 in hematopoietic cell types, activation of
the Erk pathway and induction of chemotaxis, are not signi¢-
cantly altered when internalization of SSTR2 is prevented by
truncating the C-terminal region of the receptor.
2. Materials and methods
2.1. Plasmid construction
Human SSTR2 cDNA (a kind gift from Dr G.I. Bell, Howard
Hughes Medical Institute, Chicago, IL, USA) was excised from the
pBluescript vector and inserted into the BamHI/SalI site of the eu-
karyotic expression vector pBABE [16]. The LLCAA mutant
(SSTR2-L360/361A) and the deletion mutant (SSTR2-v342) were con-




CCG), T3-R (5P-GCGCAATTAACCCTCACTAAAGGG), v342-F
(5P-GGAGTGACTGAAAGCAGGACAAATCC) and v342-R (5P-
TCCTGCTTTCAGTCACTCCGCTTCCCC). The 5P segment of mu-
tant SSTR2-L360/361A was ampli¢ed using SH2/592-F and SH2/
1172LL-R, and the 3P segment using SH2/1153LL-F and T3-R. The
5P segment of mutant SSTR2-v342 was ampli¢ed using SH2/592-F
and v342-R, and the 3P segment using v342-F and T3-R. Products
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of the primary PCRs were isolated, mixed 1:1, and used as a template
for a secondary PCR with SH2/592-F and T3-R. The products were
digested with BstEII and SalI and cloned into pBABE containing
wild-type (wt)-SSTR2, which had also been digested with these en-
zymes. The authenticity of all mutants was veri¢ed by restriction-
enzyme analysis and DNA sequencing.
2.2. Cells and transfections
The IL-3-dependent murine myeloid cell line 32Dcl10 [17] was
maintained in RPMI 1640 medium supplemented with 10% fetal
calf serum (FCS) and 10 ng/ml murine IL-3 at 37‡C and 5% CO2.
To obtain stable transfectants, cells were electroporated with 10 Wg
PvuI-digested pBABE, pBABE[wt-SSTR2], pBABE[SSTR2-L360/
361A] and pBABE[SSTR2-v342], using a progenitor apparatus set
at 230 V, 100 WF, and 1 s. After 48 h of incubation, cells were selected
with puromycin at a concentration of 1 Wg/ml. Multiple clones were
expanded for further analysis.
2.3. Flow cytometry
To determine SSTR2 expression levels, cells were incubated with 50
nM of Fluo-somatostatin1 (Fluo-SST; Advanced Bioconcept, Mon-
treal, QC, Canada) for 45 min at room temperature in the dark with
non-speci¢c binding assessed by including 100-fold excess of (D-Trp8)-
SST-14 (BACHEM AG, Switzerland). Cells were subjected to £ow-
cytometric analysis on a FACScan (Becton-Dickinson, Sunnyvale,
CA, USA).
2.4. Internalization experiments
The SST analog [Tyr3]octreotide (Novartis Pharma, Basel, Switzer-
land) was iodinated with 125I by chloramine-T method and puri¢ed by
high-performance liquid chromatography, as described previously in
detail [18]. The speci¢c radioactivity of the radioligand was approx-
imately 2000 Ci/mmol. Internalization of the radioligand was assessed
as described previously [19]. In brief, 32D[wt-SSTR2] cells were incu-
bated with approximately 200 000 cpm [125I^Tyr3]octreotide (0.1 nM
¢nal concentration) at 37‡C for the times indicated. Excess unlabeled
octreotide (1 WM; Novartis, Basel, Switzerland) was added in control
incubations to determine non-speci¢c membrane binding and internal-
ization. After incubation, surface bound radioligand was removed
with 1 ml acid wash (20 mM sodium acetate, pH 5.0) for 10 min
[20]. Internalized radioligand was measured as acid-resistant counts
in 0.1 N NaOH extracts of acid washed cells [20].
Internalization was also analyzed by £ow cytometry. For this pur-
pose, cells were incubated at 37‡C with octreotide in internalization
medium (RPMI 1640+0.25% bovine serum albumin (BSA)). To ter-
minate the incubation, cells were washed twice with ice-cold internal-
ization medium. Cell surface-bound ligand was removed by resus-
pending the cells in 1 ml sodium acetate (20 mM) in Hanks’
balanced solution, pH 5.0 (HBSS-Ac), and incubating for 10 min at
room temperature. Subsequently, cells were washed with PS (PBS+1%
FCS) to remove the HBSS-Ac, stained with Fluo-SST and subjected
to £ow-cytometric analysis on a FACScan (Becton-Dickinson, Sunny-
vale, CA, USA) as described above.
2.5. Cell lysates and Western blotting
Preparation of cell lysates and Western blotting was performed as
described [21]. Cells were stimulated with 1036 M octreotide in RPMI
1640, with 100 ng/ml granulocyte-colony stimulating factor (positive
control) or with RPMI 1640 alone. Antibodies used for Western blot-
ting were K-Erk1 and K-phospho-Erk (Tyr204) (Santa Cruz Biotech-
nology Inc, Santa Cruz, CA, USA).
2.6. Migration assay
Migration was assessed in transwell culture dishes with 5 Wm pore
¢lters (Transwell, 6.5 mm diameter, 24-well cell clusters; Costar, Cam-
bridge, MA, USA). Cells (1^2U105) suspended in 100 Wl of migration
bu¡er (Iscove’s medium, 0.5% BSA) were placed in the upper cham-
ber. Migration bu¡er (0.6 ml) containing increasing concentrations of
octreotide was placed in the lower chamber of the transwell system.
Chambers were maintained at 37‡C, 5% CO2, for 4 h. Cells that had
migrated into the lower chamber were counted using a cell counter
(CASY01/TTC, Scha«rfe Systems, Germany).
3. Results and discussion
3.1. Expression of SSTR2 and SSTR2 mutants on myeloid
32D cells
The structural features of two mutants of SSTR2, SSTR2-
Fig. 1. Expression of SSTR2 constructs in 32D cells. A: The carboxyl-terminal sequences of SSTR2 and position of mutations. Asterisks indi-
cate potential PKA/PKC phosphorylation sites. B: Flow-cytometric analysis of receptor expression on representative clones of 32D[wt-SSTR2],
32D[vSSTR2], 32D[SSTR2-L360/361A] and 32D parental. Amount of £uorescence after labeling with Fluo-SST is shown by the solid lines.
The broken lines represent the £uorescence that remains after displacement of Fluo-SST by 100-fold molar excess of non-labeled SST.
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v342 and SSTR2-L360/361A are shown in Fig. 1A. Upon
transfection in 32D cells, membrane expression of SSTR2
wt and mutants was determined by FACS analysis. Cell clones
expressing equivalent levels of receptor proteins were selected
for further analysis (Fig. 1B). Parental, as well as empty-plas-
mid controls, did not express endogenous SSTR, as con¢rmed
by RT-PCR (data not shown) and FACS analyses (Fig. 1B).
3.2. Ligand-induced internalization of SSTR2 in
hematopoietic cells
Previously, it was shown that SSTR3, SSTR4 and SSTR5
are internalized upon ligand binding and that internalization
requires an intact C-terminal region of the receptor proteins
[5,8,9,22,23]. In contrast, SSTR1 did not internalize upon con-
tinued ligand treatment [4,24]. We determined kinetics of
binding and internalization of [125I^Tyr3]octreotide by
32D[wt-SSTR2] cells (Fig. 2A). The membrane bound fraction
of radiolabeled octreotide increased rapidly during the ¢rst 30
min and then gradually declined to approximately 25% of
maximal values after 240 min of incubation. Internalization
of radioligand reached a plateau at 60 min with approxi-
mately 75% of the dose of radioligand internalized.
3.3. Internalization and signaling function of SSTR2 mutants
The kinetics and magnitude of internalization of SSTR2
and mutants with di¡erent concentrations of ligand were de-
termined by £ow cytometry using Fluo-SST. Based on the
results from the radioreceptor assay, the analysis was per-
formed 15 min, 30 min, 60 min and 120 min after initiation
of incubation with octreotide. An example of this analysis on
32D[wt-SSTR2] is shown in Fig. 2B. Subsequently, the inter-
nalization kinetics of wt-SSTR2 and SSTR2-v342 were com-
pared. Whereas 60% of wt-SSTR2 was internalized upon a 15-
min incubation with 1039 M of octreotide, cell surface expres-
Fig. 2. Internalization of SSTR2 mutants. A: Time course of membrane binding and internalization of [125I^Tyr3]octreotide by 32D[wt-SSTR2]
cells. Values are expressed as percent of maximum speci¢c binding and internalization (maximum surface-bound: 2.3%; maximum internaliza-
tion: 78%). Representative graph is shown of three independent experiments. B: FACS analysis of octreotide-induced internalization of SSTR2.
32D[wt-SSTR2] cells were incubated with octreotide for 30 min, 1 h and 2 h at 37‡C at the concentrations indicated. After washing with acid
to remove unbound and surface-bound ligand, cells were stained with Fluo-SST or with Fluo-SST and 100-fold molar excess of non-labeled
SST to determine non-speci¢c binding (shaded histograms). C: Comparative FACS analysis as performed under (B) on 32D[wt-SSTR2],
32D[SSTR2-v342] and 32D[SSTR2-L360/361A] with 1039 M of octreotide. Results are expressed as percentages of speci¢c Fluo-SST-binding at
time zero. D: E¡ect of PKC inhibitor GF109203X and PKA inhibitor H89 on internalization of wt-SSTR2 and SSTR2-L360/361A. Cells were
preincubated with the inhibitors for 30 min and 1 h at 37‡C and further treated as under (C). A representative graph of three independent ex-
periments is shown.
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sion of SSTR2-v342 was hardly a¡ected by ligand binding
(Fig. 2C). These results con¢rm that the C-terminal part of
SSTR2 contains motifs that are crucial for internalization
[8,23,25]. However, it cannot be excluded that these sequences
are also involved in the control of recycling of the receptor to
the membrane.
Serine and threonine residues in the C-terminus of SSTR
are phosphorylated by di¡erent serine/threonine kinases and
have been implicated in agonist-induced desensitization and
internalization of GPCR’s [8]. These kinases include the sec-
ond-messenger kinases protein kinase A (PKA) and protein
kinase C (PKC). However, both PKA and PKC inhibitors
H89 and GF109203X only partly reduced octreotide-induced
internalization of wt-SSTR2 (Fig. 2D).
The C-terminus of SSTR2 also comprises a dileucine motif,
L360L361 in the context TQRTLL, that could potentially
function as a binding site for adapter proteins involved in
internalization and intracellular protein tra⁄cking [26,27].
Mutation of this motif (L360/361A) resulted in a signi¢cant
reduction of ligand-induced internalization (Fig. 2C). Interest-
ingly, internalization of SSTR2-L360/361A could be com-
pletely blocked by GF109203X and partially by H89, indicat-
ing that mechanisms linked to the dileucine motif and PKA or
PKC-mediated phosphorylation cooperate in the internaliza-
tion of SSTR2 (Fig. 2D). Dileucine motifs are also present in
the C-tail of SSTR3 (FRRVLL and SKEQQLL) and SSTR4
(LRCCLL), but their role in internalization remains to be
established.
GPCRs are also phosphorylated by members of the G-pro-
tein receptor kinase (GRK) family, which results in binding of
the receptors to L-arrestin [6,28,29]. Recent work on the L-
adrenergic receptor has suggested that L-arrestin functions as
an adapter molecule that connects the receptor to the clathrin-
mediated endocytosis machinery and to the cytoplasmic tyro-
sine kinase c-Src. Interaction of the L-adrenergic receptor with
clathrin is required for the activation of Erks [7]. We found
that inhibition of GRK activity by using the non-selective
GRK inhibitors, Zn2 and heparin [30], did not a¡ect SST-
induced receptor internalization and Erk phosphorylation in
32D[SSTR2] cells (data not shown). Rather, Erk phosphory-
lation was sustained after activation of the internalization-de-
fective SSTR2 mutants (Fig. 3A). In addition, the Src inhib-
itor PP1 had no e¡ect on SSTR2-mediated Erk activation
(data not shown). Thus, unlike L-adrenergic receptor, GRK-
mediated internalization and c-Src activity are not critical for
SSTR2-induced Erk activation in hematopoietic cells. As ex-
pected, no octreotide-induced activation was seen in 32D pa-
rental cells that lack expression of SSTR (Fig. 3B).
3.4. SST-induced migration of hematopoietic cells is not
in£uenced by SSTR2 internalization
SST exerts multiple e¡ects on cells of the neuroendocrine
and immune systems, mainly as an inhibitor of secretory and
proliferative responses. We have recently identi¢ed a novel
function of SST in the hematopoietic system, where it acts
as a potent chemoattractant for normal and leukemic primi-
tive progenitor cells expressing SSTR2 [10,15]. The migratory
responses of hematopoietic cells to SST showed a typical bell-
Fig. 3. Octreotide-induced phosphorylation of Erk1 and Erk2 in (A) 32D[wt-SSTR2], 32D[SSTR2-v342], 32D[SSTR2-L360/361A] and (B) 32D
parental cells. Cells were treated with 1036 M octreotide (Oct) at 37‡C for the times indicated. As a positive control, stimulation with 100 ng/
ml granulocyte-colony stimulating factor (G-CSF) was included. Western blotting was performed using antibodies against phospho-Erk
(Tyr204). To control for equal loading, blots were stripped and restained with antibodies against total Erk.
Fig. 4. Migration of 32D[wt-SSTR2], 32D[SSTR2-v342] and
32D[SSTR2-L360/361A] cells in response to increasing concentra-
tions of octreotide. A representative graph of three experiments is
shown.
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shaped dose-response relationship, with maximal e¡ects seen
in the nanomolar range. One explanation for the loss of re-
sponse at higher ligand concentrations is that surface expres-
sion of SSTR2 rapidly becomes insu⁄cient under these con-
ditions, due to increased and sustained internalization and
proteasomal degradation of the receptor proteins. We tested
this possibility by comparing the migration properties of
32D[wt-SSTR2] with 32D cells expressing the internaliza-
tion-defective mutants SSTR2-v342 and SSTR2-L360/361A.
Strikingly, we found that the inhibition of migration at con-
centrations of 1038 M and 1037 M of octreotide was not
alleviated by the mutations in the SSTR2 C-terminus (Fig.
4), indicating that changing the internalization kinetics of
the receptor does not alter the biphasic responses of hemato-
poietic cells to SST. It thus seems most likely that SSTR2
desensitization, rather than internalization and degradation,
is the major mechanism by which hematopoietic cells down-
modulate their responses to SST.
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